20 PARK PLAZA, BOSTON, MA
Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
News
Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Reg. FD, Other Events
Material Contracts, Financial Results
Q2
Q1
FY 2024
FY 2023
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRRN14A
Contested Proxy Solicitation Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Post-Effective Amendment to Registration Statement
SEC Staff Correspondence
Correspondence